Impact of oral antipsychotic medication adherence on healthcare resource utilization among schizophrenia patients with medicare coverage

Community Mental Health Journal

Volumn 49, Issue 6, 2013, Pages 625-629

  Offord, Steve ^a   Lin, Jay ^b   Wong, Bruce ^c   Mirski, Dario ^a   Baker, Ross A ^a  

^a OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^b Novosys Health   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adherence; Costs; Healthcare utilization; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

AGED; ARTICLE; FEMALE; HEALTH CARE COST; HEALTH CARE DELIVERY; HUMAN; MALE; MEDICARE; MEDICATION COMPLIANCE; ORAL DRUG ADMINISTRATION; RETROSPECTIVE STUDY; SCHIZOPHRENIA; STATISTICS; UNITED STATES; UTILIZATION REVIEW;

ADMINISTRATION, ORAL; AGED; ANTIPSYCHOTIC AGENTS; DELIVERY OF HEALTH CARE; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MEDICARE; MEDICATION ADHERENCE; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; UNITED STATES;

EID: 84890791742     PISSN: 00103853     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10597-013-9638-y     Document Type: Article

References (20)

1. Ascher-Svanum, H.; Zhu, B.; Faries, D. E.; Salkever, D.; Slade, E. P.; Peng, X.; et al. (2010). The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry, 10, 2. doi: 10.1186/1471-244X- 10-2.
2. Carlborg, A.; Winnerbäck, K.; Jönsson, E. G.; Jokinen, J.; & Nordström, P. (2010). Suicide in schizophrenia. Expert Review of Neurotherapeutics, 10(7), 1153-1164.
3. Fors, B. M.; Isacson, D.; Bingefors, K.; & Widerlöv, B. (2007). Mortality among persons with schizophrenia in Sweden: An epidemiological study. Nordic Journal of Psychiatry, 61(4), 252-259.
4. Horvitz-Lennon, M.; Donohue, J. M.; Domino, M. E.; & Normand, S.-L. T. (2009). Improving quality and diffusing best practices: The case of schizophrenia. Health Affairs, 28(3), 701-712.
5. Howard, R.; Rabins, P. V.; Seeman, M. V.; & Jeste, D. V. (2000). Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: An international consensus. The International Late-Onset Schizophrenia Group. The American Journal of Psychiatry, 157(2), 172-178.
6. Kane, J. M. (2007). Treatment adherence and long-term outcomes. CNS Spectrums, 12(10 Suppl 17), 21-26.
7. Kelin, K.; Lambert, T.; Brnabic, A. J.; Newton, R.; Ye, W.; Escamilla, R. I.; et al. (2011). Treatment discontinuation and clinical outcomes in the 1-year naturalistic treatment of patients with schizophrenia at risk of treatment nonadherence. Patient Preference and Adherence, 5, 213-222.
8. Khaykin, E.; Eaton, W. W.; Ford, D. E.; Anthony, C. B.; & Daumit, G. L. (2010). Health insurance coverage among persons with schizophrenia in the United States. Psychiatric Services, 61(8), 830-834.
9. Kirkpatrick, B.; Messias, E.; Harvey, P. D.; Fernandez-Egea, E.; & Bowie, C. R. (2008). Is schizophrenia a syndrome of accelerated aging? Schizophrenia Bulletin, 34(6), 1024-1032.
10. Lindenmayer, J.-P.; Liu-Seifert, H.; Kulkarni, P. M.; Kinon, B. J.; Stauffer, V.; Edwards, S. E.; et al. (2009). Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response. The Journal of Clinical Psychiatry, 70(7), 990-996.
11. Llorca, P.-M. (2008). Partial compliance in schizophrenia and the impact on patient outcomes. Psychiatry Research, 161(2), 235-247.
12. Marcus, S. C.; & Olfson, M. (2008). Outpatient antipsychotic treatment and inpatient costs of schizophrenia. Schizophrenia Bulletin, 34(1), 173-180.
13. McFarland, B. H.; & Collins, J. C. (2011). Medicaid cutbacks and state psychiatric hospitalization of patients with schizophrenia. Psychiatric Services, 62(8), 871-877.
14. Meesters, P. D.; de Haan, L.; Comijs, H. C.; Stek, M. L.; Smeets-Janssen, M. M. J.; Weeda, M. R.; et al. (2012). Schizophrenia spectrum disorders in later life: Prevalence and distribution of age at onset and sex in a dutch catchment area. The American Journal of Geriatric Psychiatry, 20(1), 18-28.
15. Stephenson, J. J.; Tuncelli, O.; Gu, T.; Eisenberg, D.; Panish, J.; Crivera, C.; et al. (2012). Adherence to oral second-generation antipsychotic medications in patients with schizophrenia and bipolar disorder: physicians' perceptions of adherence vs. pharmacy claims. International Journal of Clinical Practice, 66(6), 565-573.
16. US Census Bureau. (2011). US census bureau newsroom: 2010 Census: 2010 census shows 65 and older population growing faster than total U.S. population. Retrieved from http://www.census.gov/newsroom/releases/archives/2010-census/ cb11-cn192.html.
17. Valenstein, M.; Copeland, L. A.; Owen, R.; Blow, F. C.; & Visnic, S. (2001). Adherence assessments and the use of depot antipsychotics in patients with schizophrenia. The Journal of Clinical Psychiatry, 62(7), 545-551.
18. Weiden, P. J.; & Olfson, M. (1995). Cost of relapse in schizophrenia. Schizophrenia Bulletin, 21(3), 419-429.
19. West, J. C.; Wilk, J. E.; Olfson, M.; Rae, D. S.; Marcus, S.; Narrow, W. E.; et al. (2005). Patterns and quality of treatment for patients with schizophrenia in routine psychiatric practice. Psychiatric Services, 56(3), 283-291.
20. Wu, E. Q.; Birnbaum, H. G.; Shi, L.; Ball, D. E.; Kessler, R. C.; Moulis, M.; et al. (2005). The economic burden of schizophrenia in the United States in 2002. The Journal of Clinical Psychiatry, 66(9), 1122-1129.